Navigation Links
Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Date:11/13/2008

ize genotyping in cytology negative, HPV-positive women in the same manner as high-risk HPV testing is utilized in women with ASC-US." If regulatory approvals for the Cervista 16/18 test are obtained, Hologic will be well positioned to work with professional societies, physicians and laboratories to address the needs of this group of women.

The results of these clinical trials combined with the other attributes of the test should allow Hologic to compete in the rapidly growing HPV testing market both in the U.S. and internationally. The Cervista HPV high-risk test is currently under review by the FDA in the U.S. Hologic has obtained CE marking of the Cervista HPV test and is currently in the final stages of obtaining CE Mark approval for the sample preparation component of the test. The company expects to launch the product in the EU in January 2009.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. For more information, visit http://www.hologic.com.

Forward-Looking Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the effect and adoption of the use of the Cervista HPV testing products. There can be no assurance that the tests will ach
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
2. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
3. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
6. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DALLAS , Sept. 17, 2014   OTEMR, ... 2014 Edition Complete EHR certification, which designates that the ... the Stage 1 and Stage 2 Meaningful Use measures ... and Reinvestment Act (ARRA).  ONETOUCH EMR 2.0 was certified ... an Office of the National Coordinator-Authorized Certification Body (ONC-ACB) ...
(Date:9/17/2014)... -- Bayer HealthCare will present data on hemophilia A research ... Meeting, which takes place September 18-20 in ... shared through poster presentations, showcase Bayer,s commitment to advancing ... presented in a scientific forum. "With posters ... patients, Bayer is maintaining its commitment to research in ...
(Date:9/17/2014)... 2014  Lightbeam Health Solutions announced today an ... Direct ACO) to deploy the Lightbeam population health ... care while reducing costs. Photo - ... Accountable Care Organization is the ACO operating entity ... mission is to be the premier integrated health ...
Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3
... AUSTIN, Texas, March 4, 2011 Vermillion, Inc. (Nasdaq: ... Gail Page, Vermillion,s Chief Executive Officer, will be presenting at ... Ritz Carlton, Laguna Niguel in Dana Point, CA. ... 1:00 p.m. Pacific. The presentation will be web cast and ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix , today announced it plans to ... March 11, 2011 before the open of the financial ... call with the investment community at 8:00 a.m. PT ...
Cached Medicine Technology:Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA 2Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA 3Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11 2
(Date:9/17/2014)... Leading eco-friendly beauty brand , Lotus ... new vegan and gluten-free Sugar Cane Fruit Mask. Their ... results skincare testers were looking for. , “My ... mask that provided results, and I think I accomplished ... Fruit Mask combines Willow bark (Salix Alba extract), a ...
(Date:9/17/2014)... (HealthDay News) -- Scientists have developed a blood-cleansing device, ... the way the blood infection sepsis is treated. ... said their device works outside the body like a ... toxins out of patients, blood. "Even with the ... care units at least 30 percent of the time," ...
(Date:9/17/2014)... to reduce the need for invasive biopsies in patients ... , In a new study, researchers developed a math ... kidney inflammation to interstitial fibrosis, scarring in the ... is the only existing way to reach a definitive ... model could also be used to monitor the effectiveness ...
(Date:9/17/2014)... 17, 2014 CarePoint Health became the ... 150 CarePoint Health employees participated in the Ice Bucket ... Association. The event took place on September 9, ... CarePoint Health donated $100 to the ALS Association for ... total of approximately $15,000. The Ice Bucket Challenge was ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 ... made good on their pledge to cut calories in their ... together through the Healthy Weight Commitment Foundation, pledged to remove ... and 1.5 trillion by 2015. They,ve actually reduced far more: ... pledge and exceeded their pledge," said lead researcher Shu Wen ...
Breaking Medicine News(10 mins):Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:'Biospleen' Suggests New Way to Treat Blood Infection 2Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 3Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... Minimal or Free and Best Option for Prevention;,Yet 5% Would ... Staying,Healthy., YONKERS, N.Y., Nov. 11 According to a ... to get the,flu vaccine this year, despite its being the ... long list of poor excuses,for not getting the vaccine, including ...
... First Large Scale Study Finds 73% Are From ... Consumers Union,called on hospitals today to take ... (C.-diff.) infections in light of a new report,showing ... estimates had,indicated. As the rate of hospital acquired ...
... French . , Montreal, November 11, 2008 ... that,s enabled them to reproduce complex cellular environments and ... a new study published in the journal Lab on ... Hospital Research Centre, McGill University and the Montreal Neurological ...
... is playing a key role in the largest, most ... Mental Health (NIMH) of adolescents and young adults at ... study joins the resources of Emory and seven other ... precise predictors for psychosis, and a better understanding of ...
... be an independent cause of excessive daytime sleepiness ... Researchers from Sweden performed polysomnography testing on 400 ... The apnea-hypopnea index (AHI) was calculated, and women ... very often were considered habitual snorers. Habitual snoring ...
... Proton Pump Inhibitors increase risk of major cardiovascular event by more ... for patients taking Plavix(R) Study may anticipate a role for genetic testing ... ... MHS ) today presented a study at the 2008 Scientific,Sessions of the ...
Cached Medicine News:Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 2Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 3Health News:Consumer Reports Survey: Nearly Half of Adults Won't Get Flu Vaccine, Citing Poor Excuses Like 'I Don't Get Sick' 4Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 2Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 3Health News:New Report Shows High C-difficile Infection Rates in U.S. Hospitals 4Health News:New laser method reproduces art masterworks to protein patterns 2Health News:Pivotal Emory study focuses on teens at risk for psychosis 2Health News:Pivotal Emory study focuses on teens at risk for psychosis 3Health News:Journal CHEST: Nov. highlights 2Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 2Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 3Health News:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug 4
... semi-dry electrophoretic transfer cell and PowerPac ... Efficient Transfers. Minimal Buffer Requirements. ... and Reliable Transfers. Single-Step Locking ... Capacity to Transfer Multiple Gels. ...
... Transfers depurinated DNA and RNA from agarose ... as 15 minutes ,Increases speed and efficiency ... be applied to gel ,Part of an ... and UV crosslinking in 2.5 hours, versus ...
PosiBlot 30-30 Sponges...
PosiBlot 30-30 Pads...
Medicine Products: